Options catalyst watch
Which liquid chains showed the strongest combined evidence of an options-implied catalyst on Oct 16, 2026?
A transparent 0–100 cross-sectional score built from four equally weighted groups: volatility level, front-versus-back term premium, volume/open-interest activity, and skew/smile shape. Correlated measurements share a group so one volatility surface does not receive several votes. This flags unusual pricing, not a known event or expected direction. Data through close. Descriptive only, not a recommendation.
At a glance
50 tickers qualified. First five: BRUN (84.8 · 25Δ risk reversal 100.2 pp; front IV premium 11.3 pp; volume/OI 0.12), MUU (80.3 · front IV premium 23.4 pp; volume/OI 0.14; 25Δ risk reversal 22.8 pp), VXX (80.3 · volume/OI 0.49; smile convexity 18.8 pp; 25Δ risk reversal -58.1 pp), CZR (79.5 · smile convexity -28.3 pp; volume/OI 0.30; 25Δ risk reversal -22.7 pp), CLF (79.4 · front IV premium 54.2 pp; smile convexity 25.5 pp; volume/OI 0.13).
| # | Ticker | Close | Open interest | Catalyst score / strongest drivers |
|---|---|---|---|---|
| 1 | BRUN | 8.89 | 153,338 | 84.8 · 25Δ risk reversal 100.2 pp; front IV premium 11.3 pp; volume/OI 0.12 |
| 2 | MUU | 24.34 | 154,177 | 80.3 · front IV premium 23.4 pp; volume/OI 0.14; 25Δ risk reversal 22.8 pp |
| 3 | VXX | 18.38 | 312,472 | 80.3 · volume/OI 0.49; smile convexity 18.8 pp; 25Δ risk reversal -58.1 pp |
| 4 | CZR | 28.80 | 136,347 | 79.5 · smile convexity -28.3 pp; volume/OI 0.30; 25Δ risk reversal -22.7 pp |
| 5 | CLF | 12.12 | 686,045 | 79.4 · front IV premium 54.2 pp; smile convexity 25.5 pp; volume/OI 0.13 |
| 6 | UVXY | 18.50 | 231,014 | 77.0 · volume/OI 0.60; front IV premium 26.9 pp; smile convexity -18.0 pp |
| 7 | KORU | 10.64 | 354,756 | 76.3 · front IV premium 36.1 pp; smile convexity 25.3 pp; IV rank 100 |
| 8 | RXRX | 3.46 | 315,502 | 75.3 · 25Δ risk reversal -41.2 pp; front IV premium 8.6 pp; IV rank 100 |
| 9 | AI | 11.32 | 200,700 | 75.1 · volume/OI 0.62; smile convexity -21.1 pp; IV rank 100 |
| 10 | GM | 83.96 | 268,173 | 75.0 · front IV premium 25.9 pp; IV rank 100 |
| 11 | TSCO | 33.16 | 124,121 | 74.5 · front IV premium 35.2 pp; smile convexity -22.9 pp; IV rank 100 |
| 12 | CBRS | 127.21 | 247,678 | 74.2 · volume/OI 0.29; front IV premium 15.8 pp; IV rank 100 |
| 13 | QS | 4.01 | 671,791 | 73.8 · front IV premium 33.6 pp; 25Δ risk reversal 33.7 pp; IV rank 100 |
| 14 | T | 23.43 | 979,300 | 73.6 · front IV premium 17.3 pp; 25Δ risk reversal 54.6 pp; IV rank 100 |
| 15 | DOW | 29.93 | 402,262 | 73.4 · 25Δ risk reversal -134.4 pp; front IV premium 19.1 pp; smile convexity 11.1 pp |
| 16 | CRML | 6.97 | 331,704 | 72.8 · smile convexity 28.4 pp; front IV premium 8.8 pp; IV rank 100 |
| 17 | TXN | 276.48 | 194,947 | 72.3 · front IV premium 37.8 pp; IV rank 100; volume/OI 0.08 |
| 18 | XRT | 87.02 | 102,047 | 72.2 · smile convexity -47.7 pp; front IV premium 17.2 pp; 25Δ risk reversal 47.8 pp |
| 19 | HUT | 67.75 | 324,390 | 72.1 · smile convexity -16.8 pp; front IV premium 11.4 pp; volume/OI 0.12 |
| 20 | GME | 26.81 | 1,653,759 | 71.9 · volume/OI 0.25; front IV premium 14.3 pp; IV rank 100 |
| 21 | AKAM | 87.81 | 292,423 | 71.9 · OI change 0.13σ; IV rank 100; volume/OI 0.09 |
| 22 | CRWV | 61.39 | 3,264,093 | 71.7 · volume/OI 0.32; front IV premium 15.6 pp; IV rank 100 |
| 23 | UPXI | 0.97 | 158,525 | 71.5 · front IV premium 44.4 pp; 25Δ risk reversal -175.6 pp; IV rank 100 |
| 24 | RAM | 7.94 | 111,767 | 71.0 · front IV premium 23.1 pp; smile convexity 15.4 pp; IV rank 100 |
| 25 | IBKR | 82.69 | 124,345 | 70.9 · volume/OI 0.14; front IV premium 10.6 pp; smile convexity -14.3 pp |
| 26 | BE | 221.31 | 884,042 | 70.8 · front IV premium 36.9 pp; volume/OI 0.16; smile convexity 12.1 pp |
| 27 | GRRR | 7.78 | 143,015 | 70.1 · 25Δ risk reversal -102.5 pp; front IV premium 12.9 pp; IV rank 100 |
| 28 | EWY | 150.44 | 972,725 | 70.0 · volume/OI 0.17; front IV premium 8.8 pp; IV rank 100 |
| 29 | BP | 50.21 | 381,348 | 70.0 · 25Δ risk reversal 74.3 pp; IV rank 100; volume/OI 0.07 |
| 30 | VIX | 20.06 | 15,363,220 | 69.8 · front IV premium 61.6 pp; OI change 0.12σ; volume/OI 0.15 |
| 31 | DOCN | 98.69 | 112,594 | 69.7 · front IV premium 14.8 pp; volume/OI 0.10; IV rank 100 |
| 32 | CIFR | 8.98 | 1,782,961 | 69.5 · front IV premium 12.9 pp; IV rank 100; smile convexity -9.8 pp |
| 33 | OXY | 62.38 | 678,165 | 69.4 · volume/OI 0.13; IV rank 100; smile convexity -10.6 pp |
| 34 | XBI | 144.32 | 565,719 | 69.3 · volume/OI 0.22; smile convexity 16.5 pp; IV rank 100 |
| 35 | NLY | 18.23 | 164,006 | 69.2 · smile convexity 27.8 pp; 25Δ risk reversal -118.0 pp; front IV premium 13.7 pp |
| 36 | MBLY | 7.22 | 259,167 | 69.1 · smile convexity -33.5 pp; 25Δ risk reversal -194.4 pp; front IV premium 15.1 pp |
| 37 | AXTI | 51.47 | 233,462 | 69.1 · front IV premium 9.8 pp; IV rank 100; volume/OI 0.08 |
| 38 | LUV | 39.50 | 183,113 | 68.9 · front IV premium 27.4 pp; IV rank 100 |
| 39 | STX | 639.01 | 286,515 | 68.6 · front IV premium 16.9 pp; volume/OI 0.10; IV rank 100 |
| 40 | WDC | 332.00 | 502,274 | 68.1 · front IV premium 34.8 pp; volume/OI 0.11; IV rank 100 |
| 41 | AA | 41.46 | 235,860 | 68.0 · volume/OI 0.21; IV rank 100; front IV premium 6.5 pp |
| 42 | LUMN | 4.65 | 467,873 | 67.9 · smile convexity 16.7 pp; front IV premium 12.5 pp; IV rank 100 |
| 43 | XSP | 765.94 | 777,520 | 67.8 · volume/OI 0.46; IV rank 100 |
| 44 | TIGR | 4.05 | 115,800 | 67.8 · front IV premium 22.1 pp; IV rank 100 |
| 45 | PLUG | 1.38 | 751,786 | 67.7 · 25Δ risk reversal -24.7 pp; IV rank 100 |
| 46 | LRCX | 263.94 | 495,230 | 67.6 · front IV premium 24.8 pp; IV rank 100; volume/OI 0.08 |
| 47 | IBM | 232.14 | 517,777 | 67.5 · front IV premium 36.1 pp; IV rank 100; volume/OI 0.07 |
| 48 | UEC | 7.91 | 211,169 | 67.4 · front IV premium 10.4 pp; smile convexity 12.0 pp; IV rank 100 |
| 49 | BBD | 3.96 | 235,567 | 67.3 · front IV premium 9.0 pp; IV rank 100; 25Δ risk reversal 18.0 pp |
| 50 | CMCSA | 21.90 | 761,175 | 67.1 · front IV premium 25.3 pp; IV rank 100 |
Screens describe what the data shows after the close. They are not trade recommendations; see the disclaimer and the methodology.